Phase II trial of imatinib mesylate in recurrent, biomarker positive, ovarian cancer (Southwest Oncology Group Protocol S0211)
D. S. Alberts, P. Y. Liu, S. P. Wilczynski, A. Jang, J. Moon, J. H. Ward, J. T. Beck, M. Clouser, M. Markman
International Journal of Gynecologic Cancer Jul 2007, 17 (4) 784-788; DOI: 10.1136/ijgc-00009577-200707000-00005